First-of-its-kind stem cell study re-grows healthy heart muscle in heart attack patients

Results from a Cedars-Sinai Heart Institute clinical trial show that treating heart attack patients with an infusion of their own heart-derived cells helps damaged hearts re-grow healthy muscle.

Patients who underwent the stem cell procedure demonstrated a significant reduction in the size of the scar left on the muscle by a heart attack. Patients also experienced a sizable increase in muscle following the experimental stem cell treatments.

One year after receiving the stem cell treatment, scar size was reduced from 24 percent to 12 percent of the heart in patients treated with cells (an average drop of about 50 percent). Patients in the , who did not receive stem cells, did not experience a reduction in their heart attack scars.

The study appears online at thelancet.com and will be in a future issue of the journal's print edition.

"While the primary goal of our study was to verify safety, we also looked for evidence that the treatment might dissolve scar and regrow lost heart muscle," said Eduardo Marbán, MD, PhD, the director of the Cedars-Sinai Heart Institute who invented the procedures and technology involved in the study. "This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it. The effects are substantial, and surprisingly larger in humans than they were in animal tests."

"These results signal an approaching paradigm shift in the care of ," said Shlomo Melmed, MD, dean of the Cedars-Sinai medical faculty and the Helene A. and Philip E. Hixon Chair in Investigative Medicine. "In the past, all we could do was to try to minimize heart damage by promptly opening up an occluded artery. Now, this study shows there is a regenerative therapy that may actually reverse the damage caused by a heart attack."

The clinical trial, named CADUCEUS (CArdiosphere-Derived aUtologous stem CElls to Reverse ventricUlar dySfunction), was part of a Phase I investigative study approved by the U.S. Food and Drug Administration and supported by the National Heart, Lung, and Blood Institute.

As an initial part of the study, in 2009, Marbán and his team completed the world's first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient's heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack.

The 25 patients -- average age of 53 -- who participated in this completed study experienced heart attacks that left them with damaged heart muscle. Each patient underwent extensive imaging scans so doctors could pinpoint the exact location and severity of the scars wrought by the heart attack. Patients were treated at Cedars-Sinai Heart Institute and at Johns Hopkins Hospital in Baltimore.

Eight patients served as controls in the study, receiving conventional medical care for heart attack survivors, including prescription medicine, exercise recommendations and dietary advice.

The other 17 patients who were randomized to receive the stem cells underwent a minimally invasive biopsy, under local anesthesia. Using a catheter inserted through a vein in the patient's neck, doctors removed small pieces of heart tissue, about half the size of a raisin. The biopsied heart tissue was then taken to Marbán's specialized lab at Cedars-Sinai, using methods he invented to culture and multiply the cells.

In the third and final step, the now-multiplied heart-derived cells – approximately 12 million to 25 million – were reintroduced into the patient's coronary arteries during a second, minimally invasive [catheter] procedure.

Patients who received stem cell treatment experienced an average of 50 percent reduction in their scars 12 months after infusion while patients who received standard medical management did not experience shrinkage in the damaged tissue.

"This discovery challenges the conventional wisdom that, once established, is permanent and that, once lost, healthy cannot be restored," said Marbán, The Mark S. Siegel Family Professor.

The process to grow cardiac-derived involved in the study was developed earlier by Marbán when he was on the faculty of Johns Hopkins University. The university has filed for a patent on that intellectual property and has licensed it to a company in which Dr. Marbán has a financial interest. No funds from that company were used to support the clinical study. All funding was derived from the National Institutes of Health and Cedars-Sinai Medical Center.

More information: Study online: www.thelancet.com/journals/lan… (12)60195-0/abstract

Provided by Cedars-Sinai Medical Center

5 /5 (8 votes)

Related Stories

Stem cells to repair damaged heart muscle

Jun 22, 2007

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

Heart derived stem cells develop into heart muscle

Apr 23, 2008

Dutch researchers at University Medical Center Utrecht and the Hubrecht Institute have succeeded in growing large numbers of stem cells from adult human hearts into new heart muscle cells. A breakthrough in stem cell research. ...

Stem cells to be injected into the heart

Aug 26, 2005

The University of Pittsburgh Medical Center will begin a clinical trial to determine the feasibility of injecting a patient's own stem cells into the heart.

Recommended for you

Fish oil supplements don't prevent recurrence of A-fib

12 hours ago

(HealthDay)—High doses of fish oil supplements won't prevent recurrence of atrial fibrillation (AF), Canadian researchers report. The study, funded by the Canadian Institutes for Health Research and the ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Newbeak
not rated yet Feb 13, 2012
I wonder if this will become a heart failure treatment as well.
Hengine
not rated yet Feb 13, 2012
How long does it take for treatments like this to be available to the general public?
Newbeak
not rated yet Feb 13, 2012
If it is comparable to getting a new drug approved ,I would guess about 2 and a half years.
Vendicar_Decarian
not rated yet Feb 14, 2012
I wonder if injecting the cells between the heart and the pericardium wouldn't also assist in reducing tissue damage.
DaFranker
not rated yet Feb 14, 2012
Insanity. Patenting the only known method to produce such a beneficial treatment. Let's prevent anyone else from making more of it until they pour tons of time and resources into developing a new, different process that might be much less efficient or safe.

Coming up next: Patenting a generalized stem-cell-based process to cure all forms of cancer. Naturally, keeping production low enough for said cure to have an insignificant impact on society and be extremely difficult to obtain.

Stay tuned for more stories of how Uncle Sam raped your sister!
krundoloss
not rated yet Feb 14, 2012
Wait Wait. This might actually make the patient healthier! Oh, man, we can't do that! We have to find some way for the patient to keep taking heart medication, and going to Doctor visits, and funnelling thier hard earned money into the bloated medical industry! Alright, FDA, time to do your thing! Yay, we are still rich!